|08:30 - 09:20||50 min||Registration|
|09:20 - 10:00||40 min||Opening Ceremony||KOR ENG|
|10:00 - 12:00||120 min||
Chair: Prof. Tai Hyun Park, School of Chemical and Biological Engineering, Seoul National University, Republic of Korea
|10:00 - 10:40||40 min||
The past, present and future of
COVID-19 based on the nature of the virus and the history of the virus
|10:40 - 11:20||40 min||
COVID-19: the global pandemic and progress in vaccine development
|11:20 - 12:00||40 min||
COVID-19: The Virus and Prophylaxis/Therapeutics
|12:00 - 13:00||60 min||Luncheon|
|13:00 - 14:30||90 min||
[Session 1] Science of SARS-CoV-2
Chair: Prof. Jae-Hyung Jang, Department of Chemical and Biomolecular Engineering, Yonsei University, Republic of Korea
|13:00 - 13:30||30 min||
Virus and Host – Clinical and Basic Researches for COVID-19
|13:30 - 14:00||30 min||
Introduction to Molecular Biology of Coronaviruses
|13:00 - 13:30||30 min||
SARS-CoV-2 Mutation: Causes, Consequences, and
|13:00 - 15:20||140 min||
[Session 2] Diagnosis & Prevention of COVID-19
Chair: Prof. Min-Gon Kim, Department of Chemistry, Gwangju Institute of Science and Technology , Republic of Korea
|13:00 - 13:25||25 min||
Current status of COVID-19 diagnostics solution
|13:25 - 13:50||25 min||
Molecular diagnosis of COVID-19
|13:50 - 14:10||20 min||
Molecular and immunological diagnostic tests of COVID-19 – current
status and challenges
|14:10 - 14:30||20 min||
Insights from Singapore into the clinical features and transmission of SARS
CoV2, the cause of COVID-19
|14:30 - 14:55||25 min||
Laboratory Diagnosis of COVID-19
|14:55 - 15:20||25 min||
Situation of Infection Prevention and Control for COVID-19 in Korea
|14:30 - 15:00||30 min||Coffee Break|
|15:00 - 17:40||160 min||
[Session 3] Vaccines & Therapeutics for COVID-19
Chair: Prof. Jonghoon Choi, Associate Professor and Department Head, School of Integrative Engineering, Chung-Ang University, Republic of Korea
|15:00 - 15:30||30 min||
A Step Forward Back to the Healthier World: Celltrion’s Clinical Trial Phase I
Initiation for COVID-19 Treatment
|15:30 - 16:00||30 min||
Development of hyperimmune globulin therapy against SARS-CoV-2
|16:00 - 16:25||25 min||
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved
|16:25 - 16:50||25 min||
Vaccine trend at current pandemic situation: recombinant protein, nucleic acid
|16:50 - 17:15||25 min||
COVID-19 spike protein vaccine candidate with nanoliposome and TLR4 agonist
|17:15 - 17:40||25 min||
Development of next generation glycoconjugate vaccines with bacteriophage Qbeta
|15:20 - 16:00||40 min||Coffee Break|
|16:00 - 17:30||90 min||
[Session 4] AFOB Workshop (Predicting the Economy after
Chair: Prof. Insuk Cheong, Professor, Economics, Hankuk University of Foreign Studies, Republic of Korea
|16:00 - 16:30||30 min||
Socio-economic impact and response of COVID-19 pandemic
|16:30 - 17:00||30 min||
Bioeconomy in the era of COVID-19
|17:00 - 17:30||30 min||
Investment Trends in Post COVID-19 Era
Professor Yong Seok Jeong acquired his Ph.D. in virology at the University of Texas-Austin. After studying viral pathology at Harvard Medical School, he has been a professor at Kyung Hee University in Seoul since 1995. He is studying RNA virus-host cell interaction and molecular evolution, and is currently a vice-president of the Microbiological Society of Korea and a member of the Korean Society of Virology.
The COVID-19 outbreak, which began in Wuhan, China in winter 2019, has swept the
world in less than half a year. In 2009, the Swine flu, which killed about 200,000
people due to acute respiratory infections, recorded the second pandemic after the
launch of the WHO, and COVID-19 was declared the third pandemic, making it the first
worldwide infection of coronavirus. The number of deaths caused by COVID-19, which
exceeds 600,000 already, is still less than that of the Asian flu in 1958 and the
Hong Kong flu in 1968, where more than 1-2 million people died, but the sense of
fear is much greater now.
Viruses that can spread to humans across species barriers, like as the influenza viruses originating from wild birds and the coronaviruses derived from bats, have already existed for a long time, and there will be countless types. These viruses continue to adaptively evolve through point mutations and various recombination events, and most of the time and conditions they encounter us are determined by changes in our lifestyle. Before the Industrial Revolution, the border between wild and civilization was relatively clear, but now we are crossing the border more often at much more interfaces. While bacterial infections were the main cause of the epidemic in the early days of urbanization, epidemics since the early 20th century, when antibacterial agents were found, have been dominated by viruses, and the interval between these epidemics is decreasing as rapidly as the border blurs. This is evidenced by the fact that the majority of pathogens leading to notable epidemics since the 20th century are zoonotic viruses. The characteristic of the zoonosis is that the causative agents cannot be completely eradicated, and even if it can be temporarily eliminated or contained, it is very likely to come back sooner or later. In particular, RNA virus has a high probability of producing mutant strains, and 2-3 types of SARS-CoV-2, which were classified in the early stages of COVID-19, have been diversified to 6 types in half a year. It is not yet known how these mutants will affect this epidemic from an immunological and clinical point of view, but it is time to pay special attention to changes in the genetic information of the virus. While many Asian and European countries, which had experienced the early blast of the epidemic, entered a relatively stable period at the moment, the incidence of infection is still rising in the United States, South America, and Africa. This regional time difference in the spread of epidemics, together with the newly emerged viral variants, implies the possibility that the second and the third waves of infection can continue at any time.
Currently, more than 160 vaccine candidates are being developed worldwide to restrict COVID-19, and about 20 of them are undergoing clinical trials. The development period of the vaccine, which previously took an average of 10 years, has been shortened to commercialization targets within 1-2 years through global agreement and cooperation, and various antiviral drugs are also being retargeted. This human effort will reduce the COVID-19 sacrifice, but it seems more likely to convert to endemic disease rather than elimination. Soon, but other viruses are waiting to appear on the stage and we have to prepare for them. The co-evolution between humans and viruses will continue, but the number of the victims of the new viral epidemics is entirely up to us.
Jerome Kim, M.D., is the Director General of the International Vaccine Institute
(IVI) and an international expert on the evaluation and development of vaccines. His
depth and breadth of scientific experience span basic research through advanced
clinical development. IVI’s oral cholera vaccine is used around the world to prevent
this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to
SK bioscience and PT Bio Farma, is completing Phase III testing. IVI is working on
several different vaccines against COVID-19, including the clinical testing of
Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19
vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis ,in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination. Dr. Kim has authored over 250 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology and received his M.D. from Yale University School of Medicine.
Prof. Gao obtained his PhD (DPhil) degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). His research interests include enveloped viruses and molecular immunology. His group research is mainly focusing on the enveloped virus entry and release, esp. influenza virus interspecies transmission (host jump), structure-based drug-design and structural immunology. He is also interested in virus ecology, esp. the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology. His research has recently expanded on public health policy and global health strategy. He has published more than 600 refereed papers, i.e., Cell, Nature, Science, The Lancet, NEJM, PNAS etc. He is a recipient of several international and national awards, including Nikkei Asian Prize (Japan 2014), the Gamaleya Medal (Russia 2018) and HKU Centennial Distinguished Chinese Scholar (2019).
Shin-Ru Shih got her bachelor degree in Medical Technology and master degree in Biochemistry from National Taiwan University and her Ph.D. in Biochemistry and Molecular Biology from Rutgers University, New Jersey, USA. She established a Molecular Virology Laboratory at Chang Gung University in 1996 and was appointed Medical Director in Clinical Virology Laboratory, Chang Gung Memorial Hospital in 1998. She also started the Research Center for Emerging Viral Infections at Chang Gung University in 2009, and took the lead as center director since then. Her team have been studying various aspects of emerging RNA viruses, including identification of viral pathogens during outbreaks, mechanistic studies of pathogenesis, and development of vaccines and antiviral agents.
The novel human coronavirus disease COVID-19 has become the fifth documented pandemic since the 1918 flu pandemic. The coronavirus was officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses based on phylogenetic analysis. Because the virus is highly contagious, it rapidly spreads and continuously evolves in the human population. This talk will discuss laboratory diagnosis of SARS-CoV-2, including culture-based virus isolation for evaluation of potential infectivity of clinical specimens and viral genomic surveillance in Taiwan. Our results revealed that in addition to viral RNA copy numbers, the integrity of the viral genome should be considered when evaluating the infectivity of clinical specimens from COVID-19 patients. Sequence analysis of SARS-CoV-2 in Taiwan reveals novel ORF-8 deletion mutant and clade possibly associated with infections in middle East. Regarding the developments of antiviral agents, clinical physician scientists at CGMH have obtained the plasmablast-derived monoclonal antibodies from COVID-19-infected patients and several antibodies have been identified to have great inhibitory effects on different clades of SARS-CoV-2. Moreover, our team applied EditCell Virology platform (genome-wide CRISPR-based system) to screen host factors that are important for RNA virus replication. We identified X protein as a crucial factor not only for coronaviruses but also for dengue viruses and enteroviruses infections. Based on this finding, our team also identified two FDA-approved drugs targeting to X protein, that are able to decrease the viral load of these RNA viruses, including SARS-CoV-2. The team is now seeking the opportunity with international pharmaceutical companies to conduct clinical trails, which may treat COVID-19 patients and contain virus spread.
SARS-CoV-2, a caustic agent of COVID-19, is the first virus in human history that totally transformed hundreds of countries' daily lives in just a few months. It is a strain of coronavirus, known as a less severe pathogen that causes a common cold. Only recently, two new strains of human coronaviruses, SARS-CoV-1 and MERS-CoV, arose as serious threats to public health. In this talk, Hyeshik Chang introduces the molecular and genomic structures and the coronaviruses' life cycle. Scientists are revealing the virus's uncommon molecular machinery at an unprecedented speed for the first half of 2020. Besides the established knowledge of the coronavirus virology, his talk will also include the recent research directions by basic molecular biologists.
Prof. Judd F. Hultquist is an Assistant Professor in the Division of Infectious Diseases at Northwestern University in Chicago, Illinois, USA. His lab specializes in the design and adaptation of high-throughput technologies for the study of virological systems and host-pathogen interactions. Using genomic, functional genomic, and proteomic methodologies, his lab studies the molecular basis of viral infection and pathogenesis, including work on Human Immunodeficiency Virus (HIV), Influenza A Virus (IAV), Respiratory Syncytial Virus (RSV), Ebola Virus (EBOV), and SARS Coronavirus 2 (SARS-CoV-2). Through these efforts, Prof. Hultquist and his team ultimately hopes to strengthen the bridge from big data to targeted discovery to clinical application for the development of next-generation therapeutics and the advancement of human health.
As SARS Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019
(COVID-19), has spread across the globe, it has been continuing to accumulate
genetic mutations - diversifying, evolving, and adapting to its new human hosts. All
viruses mutate over time, and this internal ‘molecular clock’ can be extremely
useful for scientists trying to understand the how, where, and when the virus has
spread. A vast majority of these genetic changes will be neutral, with no
significant impact on the virus or the host. Some of these genetic changes may be
detrimental to the virus, but these often escape notice as the viruses that contain
them fail to propagate. Under rare circumstances, however, a mutation will arise
that makes a virus better able to replicate and survive. Understanding the causes
and consequences of these mutations is important for informing vaccine development,
therapeutic design, clinical practice, and public health measures, but this can be a
In this presentation, we will explore how scientists are monitoring SARS-CoV-2 mutations and what we can learn from them, using my hometown, Chicago, Illinois, USA, as an example. In collaboration with hospitals across the Chicago metropolitan area, my lab has been working to determine the whole genome sequences of SARS-CoV-2 viruses from COVID-19 patients. These efforts have discovered a number of distinct viral families or ‘clades’ circulating in the Chicago area, consistent with multiple independent introductions of the virus over the course of several months. While two of these clades reflect the epidemic elsewhere in the USA, New York and Washington specifically, one of the clades appears relatively unique to Chicago and is very closely related to the original viruses isolated from China. Over time, one of these viral clades has become dominant not only across the city, but across the entire globe, suggesting the emergence of a mutation that improves viral fitness. Indeed, when we examine the clinical records of patients infected with viruses from this clade, they have higher viral loads in their upper respiratory tract than other COVID-19 patients. Fortunately, these viruses do not appear to be associated with more severe disease or worse clinical outcome.
While a lot more research needs to be done to determine the impact of these mutations on viral replication and pathogenesis, they are already being used track the movement of the virus and inform public health practices. Molecular and structural modeling is likewise being used to predict whether any of these mutations may provide resistance to therapeutics and vaccines currently under development. As the pandemic continues, efforts to understand the causes and consequences of SARS-CoV-2 mutations will likewise continue, providing important resources and unique opportunities to combat this deadly disease.
2014. Dec. – present / Boditech Med. Inc., Korea
Marketing team leader / Principle scientist
2013.Jan.-2014. Nov. / Samsung Medical Center (SMC), Korea Principal Scientist, Team leader of Translational Research Organization (TRO), Institute for Refractory Cancer Research (IRCR)
2012. Apr. – 2012.Dec./ Cha Cancer Institute, Korea Postdoctoral fellow, Cha Cancer Institute, Korea
2007 – 2012 Jan. Cancer Institute of New Jersey, USA Postdoctoral fellow, Section of Urology oncology, USA
2006 Ph.D., Rutgers University/University of Medicine and Dentistry of NJ, USA
1993-1998 Cancer Research Center, Seoul National University Hospital, Korea Research fellow, Laboratory of Cell Biology
1993. M.S. Seoul National University, Korea
1991. B.S. Seoul National University, 1991, Seoul, Korea
COVID-19 is new diseases caused by SARS-CoV-2, a new virus that had no vaccine and
treatment medicine. Vaccine and treatment drug are under development, meanwhile,
best response to this disease is fast screening, quarantine, to block the spread of
Prompt and effective diagnosis of COVID-19 patient is critical in current situation. RT-PCR is accurate and confirmatory test for COVID-19. However, due to nature of molecular test, significant resources and time is required to get result. Thus, in pandemic situation or mass screening, RT-PCR has its limitation in its throughput and required resources including facility and trained manpower. Also, RT-PCR is not available in Low and Middle Income Countries (LMICs). Alternative diagnosis methods are antibody test and antigen test. There are limited number of antigen test is available and antibody test is providing clinical information, but it is not main diagnostics tool. Boditech Med Inc. developed total solution for the COVID-19 diagnosis, including antigen test and antibody test in together with RT-PCR kit. With these diagnostics tools, Boditech is trying to help society in COVID-19 situation. Based on our experience and feedback from our end users over the world, we are continuing to improve our tests, to provide better diagnostics solution and would like to share information with healthcare provider and academic researchers.
Dr. Lee is Associate Professor in Radiology at Harvard Medical School, Director of the Biomedical Engineering Program at the Center for Systems Biology, Massachusetts General Hospital (MGH), and Hostetter MGH Research Scholar. He received his Ph.D. in Physics from Harvard University and completed his postdoctoral training at MGH. Dr. Lee has extensive experience in nanomaterials, biophysics, microfluidics, and electrical engineering. His research focuses on developing novel biomedical sensors for clinical applications, for example, the world’s smallest portable NMR device, integrated circuit (IC) chips for cancer cell detection, a point-of-use device for allergen detection, and a fast PCR platform for infection diagnostics. Many of these systems have been translated clinical applications.
Rapid spread of coronavirus disease 2019 (COVID-19) is ravaging the globe. Since its
first report in December 2019, COVID-19 cases have exploded to over 3.9 million in
four months, claiming more than 270,000 lives. Implementing fast and widespread
diagnostic tests is paramount to contain COVID-19, given the current lack of an
effective therapeutic or vaccine. This presentation focuses on a broad description
of currently available diagnostic tests to detect either the virus (SARS-CoV-2) or
virusinduced immune responses. I will specifically explain the working mechanisms of
these tests and compare their analytical performance. These analyses will assist in
selecting most effective tests for a given application, for example, epidemiology or
global pandemic research, population screening, hospital-based testing, home-based
and point-of-care testing, and therapeutic trials. Finally, I will lay out the
shortcomings of certain tests and future needs.
· Weissleder R, Lee H, Ko J, Pittet MJ (2020) COVID-19 diagnostics in context. Sci Transl Med 12, eabc1931. doi: 10.1126/scitranslmed.abc1931.
· Kilic T, Weissleder R, Lee H (2020) Molecular and immunological diagnostic tests of COVID-19 – current status and challenges. iScience, in press.
Paul Ananth Tambyah is currently Professor of Medicine at the National University of Singapore and Senior Consultant Infectious diseases physician at the National University Hospital. After completing medical school at the National University of Singapore and military service in the Singapore Armed Forces medical corps, he trained in Infectious Diseases at the University of Wisconsin under Professor Dennis Maki. Since returning to Singapore more than 20 years ago, he has held a variety of appointments including founding head of the division of infectious diseases at the national university of Singapore and past President of the Society of Infectious Diseases (Singapore). He is currently President of the Asia Pacific Society of Clinical Microbiology and Infection and President-elect of the International Society of Infectious Diseases. His research interests are healthcare associated infections primarily device associated infections and emerging infectious diseases.
Singapore was one of the first countries outside China affected by the SARS CoV2 virus when a traveler from Wuhan was diagnosed in Singapore on Jan 23. Local transmission followed in early Feb and a number of clusters arising from imported cases were identified. A very rigorous program of contact tracing, isolation and quarantine as appropriate was instituted with widespread testing and use of molecular and serological tools to establish links between cases detected. This helped achieve good control through Feb and early March. Unfortunately, by end March, widespread outbreaks in migrant worker dormitories and elsewhere led to a significant lockdown which lasted two months before being lightened somewhat. During this period, we have learned a lot about the transmissibility of the virus as well as discovered some fascining insights into the host response to the virus and the strong possibility of long lasting immunity to the virus which has implications for vaccine development.
Dr. Sung is a laboratory director and professor at the Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center. His research interests include clinical microbiology and infectious diseases.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus
responsible for a current pandemic causes a syndrome characterized by fever, cough,
and dyspnea progressing to acute respiratory distress syndrome. Early detection of
SARS-CoV-2 and immediate isolation of infected patients from the susceptible
population is important for preventing the spread of infection. The WHO recommends
nucleic amplification tests for laboratory confirmation of coronavirus disease 2019
(COVID-19). Real-time RT-PCR is currently the most reliable diagnostic method for
COVID-19. As of May 15, 2020, six real-time RT-PCR reagents have been approved for
emergency use (emergency use authorization, EUA) in Korea. Recently, Korean Society
for Laboratory Medicine (KSLM) and the Korea Centers for Disease Control and
Prevention (KCDC) published guidelines for diagnosing COVID-19 in clinical
laboratories in Korea. The guidelines include the selection of test subjects,
selection of specimens, diagnostic methods, interpretation of test results, and
biosafety. However, many practical and technical issues are frequently inquired,
regarding nucleic acid extraction, nucleic acid amplification reagents, and
interpretation of test results. Here, I would like to review the COVID-19
diagnostics and provide supplementary information to the practical issues and
solutions to COVID-19 real-time RT-PCR testing. And I will briefly review the
antigen test of SARS-CoV-2 and serology for the COVID-19.
As the experience of the Middle East respiratory syndrome (MERS) outbreak of 2015 in Korea, an epidemic of emerging infectious diseases necessitate clinical laboratories to conduct relevant tests at a large scale in a short period of time with EUA kits. Owing to the increasing diagnostic capacity, our nation was able to slow down the COVID-19 epidemic without enforcing city-wide lockdowns or collapse of the national healthcare system. Diagnostic capacity requires further improvement such as addressing the need to shorten the turnaround time for testing. Recently, several commercial near point-of-care (POC) nucleic acid tests (NATs) received EUA from the U.S. FDA. It is expected to be useful in these urgent situations.
1. Sung H, et al. Clin Chem 2020 Apr 22:hvaa097.
2. Hong KH, et al. Ann Lab Med 2020;40:351-60.
I have been working for pharmaceutical company since 1997. I started my career at Korean Green Cross Company in the area of purification and method development and characterization for the cytokine and coagulant factor product. After joining to Celltrion, I was involved in developing purification process for monoclonal antibody products and late stage downstream process development. At the same time, I experienced Project Leading for several products. Now I am leading Research and Development Center of Celltrion as a Head.
As one of the leading pioneers in the global biopharmaceutical industry, Celltrion
once again joins forces with the world to tackle Covid-19 pandemic and protect human
lives. The highly anticipated clinical trials of Coronavirus antibody therapeutics,
of which Celltrion obtained an approval for Phase I from Ministry of Food and Drug
Safety (MFDS) of Korea on July 17th, is planned to expand up to approximately 200
moderate and 300 severe patients in subsequent phase II and III.
The antibody in development is already partially proven safe in non-clinical trials with cynomolgus monkeys, and effective in ferrets and hamsters—ferrets showed viral titer decreased to near zero after 2 and 6 days of medication, while hamsters showed a significant decrease in inflammation level. In addition, because the drug is composed of monoclonal antibodies with robust neutralization capability, the new treatment is unlikely to cause antibody-dependent enhancement (ADE).
Just as Celltrion, many pharmaceutical companies have joined in developing therapeutics and vaccines for the disease—currently over 50 companies worldwide are in the race. Yet the biggest challenge in developing treatments is posed by the very nature of coronavirus itself. Thus Celltrion, equipped with cutting-edge antibody development and manufacturing technology, is putting efforts in innovative antibody therapeutics. The “super antibody” under development in Celltrion lab demonstrated to maintain stronger neutralizing capacity against Coronavirus variants in the test conducted at Korea Centers for Disease Control.
The effort goes beyond the current pandemic: as global community is repeatedly plagued by numbers of different transmissible diseases, Celltrion is taking a keen interest in providing the world with more advanced and effective solutions. Antibody therapeutics for influenza and Middle East Respiratory Syndrome (MERS) and Coronavirus antigen & antibodies test kits are all a part of Celltrion’s endeavor to make the world healthier.
Celltrion’s GMP-compliant and efficient manufacturing capability is the key to transfer these innovation into practical, affordable and readily available solutions. Celltrion’s production facility is not only prepared to apply the most recent lab inventions into large-scale manufacturing, but also flexible in production slot adjustment. Celltrion’s ability to control and operate both research & development and manufacturing will enhance its opportunity to contribute to human health, and serve the most pressing needs of our community and society today.
Hyouna Yoo is heading the R&D Center at GC Pharma, with 20 years of relevant
experience in the biotechnology and pharmaceutical industries. She has broad
experience across drug discovery and clinical development programs,
project/portfolio management and business development.
She started her career at Mogam Institute for Biomedical Research in 1999, at where she was focused on development of vaccines against HCV and HBV. Prior to joining GC Pharma, she spent 10 years in developing monoclonal antibody therapeutics in various disease areas such inflammation and cancer at ISU Abxis.
She received her Ph.D. and B.S degrees in Immunology from and Seoul National University and Ewha Womans University, respectively.
Passive immunity is the transfer of active humoral immunity of antibodies made
outside individual’s own immune system. Passive immunity can occur naturally or it
can also be induced artificially, when high levels of antibodies specific to a
pathogen or toxin are transferred to non-immune persons through blood products that
contain antibodies, such as in immunoglobulin therapy. Hyperimmune globulins are
designed to give a patient passive immunity against a specific disease, when there
is a high risk of infection and insufficient time for the body to develop its own
immune response, or to reduce the symptoms of diseases.
During this unprecedented health crisis, plasma from individuals who have recovered from COVID-19, called convalescent plasma, has been proved as one of the potential therapeutic option. Through these findings with convalescent plasma, GC Pharma believe in the therapeutic potential of human plasma by means of passive immunization. This plasma from recovered COVID-19 patients contains antibodies which are specific against SARS-CoV-2, the virus that causes COVID-19, and are anticipated to help the body fight the infections disease.
GC Pharma is applying its broad knowledge and deep expertise in producing immunoglobulines to manufacture a specific anti-SARS-CoV-2 hyperimmune globulin for COVID-19, whose safety and efficacy will be evaluated in upcoming clinical trial in South Korea.
1."Vaccines: Vac-Gen/Immunity Types". www.cdc.gov. Retrieved 2015-11-20.
2.“Microbiology and Immunology On-Line Textbook”: USC School of Medicine
3."Passive Immunization - Infectious Diseases". Merck Manuals Professional Edition. Retrieved 2015-11-12.
4.“The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study”, Yang et al. 2020.
Dr. Seungtaek Kim received his Ph.D. in biochemistry from Iowa State University in 2004. For postdoctoral research, he moved to Howard Hughes Medical Institute at University of Wisconsin-Madison and studied hepatitis B virus with Dr. Paul Ahlquist. In 2007, his research focus was changed to hepatitis C virus when he moved to Dr. Stan Lemon’s Lab at UTMB/University of North Carolina. His hepatitis virus research continued even after he came back to Korea in 2012 to join the Yonsei Liver Center at Severance Hospital. In 2017, he became a Head of Zoonotic Virus Laboratory at Institut Pasteur Korea and started to investigate emerging viruses (e.g., MERS-CoV, SARS-CoV-2, SFTS, Zika and dengue viruses) in addition to the drug-resistant hepatitis viruses. Currently, his research focuses on the development of therapeutic interventions (i.e., small molecule inhibitors and therapeutic antibodies) against these emerging viruses to control the current COVID-19 pandemic.
COVID-19 is an emerging infectious disease and was declared as a pandemic by WHO. Currently, there is no effective vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 µM < IC50 < 10 µM) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide – were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In the near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.
Dong Soo Kang, PhD, is Head of Biosafety Testing Services (BTS) in Samsung Biologics and is in charge of building and expanding biosafety services required for biopharmaceutical manufacturing. Prior to join Samsung Biologics, he had worked for CRO/CDMO industries as in viral clearance/virus production process, such as WuXi Advanced Therapies Viral Vector Manufacturing, WuXi Biologics and WuXi AppTec, Philadelphia, USA. He was a founding member to build up WuXi Biologics’ biosafety testing facility in China as a member of Site Facility Management team. Educational background is Protein Biochemistry and Molecular Pharmacology studied at University of Texas Health Science Center at San Antonio and Kimmel Cancer Center at Thomas Jefferson University.
Modern medicines provide great benefit to quality of living and health by maintaining symptoms, curing diseases and even protecting us from potential diseases as a form of vaccines. In recent pandemic situation, a concept of Disease X (by WHO) becomes regarded as more important, which allows us prompt reactions to hypothetical and unknown pathogens. To achieve this goal, flexible platforms to produce vaccines against a broad range of pathogens with agile manufacturing capability is prerequisite. Although traditional vaccine is widely used as treated natural pathogens, proof of safety takes longer to be approved. New generation of vaccines such as recombinant subunits, nucleic acids and even carrier virus has been developed in last two decades. Since human safety should be considered first even in such a pandemic situation, experimental approaches take advanced technologies to reduced or avoid intrinsic safety issues in traditional vaccine platforms.
Dr. Yeongok Baik has more than 30 years experiences of vaccine development and
commercial production in biotechnology industry, starting his career at
pharmaceutical division of CJ Corporation.
He is currently a CEO at EuBiologics Co., Ltd. incorporated in 2010, and which has focused to develop vaccines and biopharmaceutical technology for public health.
He graduated from Seoul National University in Veterinary Medicine and has a Ph.D in Life Science from Korea University.
The spike protein(S1) and RBD(Receptor binding domain) part of COVID-19 virus are
the major target for vaccine development. Admixing recombinant S1 or/and RBD protein
with nanoliposome containing CoPoP(cobalt porphyrin-phospholipid) and recombinant
EcML(recombinant E. coli producing Monophospho-lipid A) resulted in rapid,
particulate surface display of the conformationally intact antigens. The candidate
produced higher neutralizing antibodies and T-cell responses compared to other
vaccine adjuvants after immunization in mice and ferrets. The new nanoliposome
adjuvant system could be a good COVID-19 vaccine candidate following the
pre-clinical test and human trial for safety and immunogenicity.
Keywords: Spike protein; RBD; Nanoliposomes; CoPoP; EcML; Vaccine candidate
1. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes, Jasmin Federizon et al., Vaccine. 2020 Jan 22;38(4):942-950.
2. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes, Wei-Chiao Huang et al., Nature Nanotechnology volume 13 , pages 1174 – 1181 ( 2018 )
Dr. Xuefei Huang is an MSU Foundation Professor at the Departments of Chemistry and Biomedical Engineering of Michigan State University, and a member of the Institute for Quantitative Health Science and Engineering. His research interests are mainly aimed at studying chemistry and biology of carbohydrates. A major focus is to develop new methodologies for synthesis of complex glycans and glyco-conjugates. In addition, his group is actively investigating novel approaches to boost immune responses as next generation anti-cancer and anti-microbial vaccines. His group is also interfacing carbohydrate chemistry with nanotechnology for molecular imaging and targeted drug delivery. Dr. Huang has won multiple awards, including the New Investigator Award, the Horace S. Isbell Award and the Melville L. Wolfrom Award from the American Chemical Society. He was elected a Fellow of the American Association for Advancement of Science, and a Fellow of the American Chemical Society.
Vaccines have had tremendous benefits to human society. With the increasing
awareness of vaccine safety, conjugate vaccines have become attractive for vaccine
design. For successful conjugate vaccines, the immunogenic carrier moiety is
critical. Previously, we have demonstrated that bacteriophage Qbeta nanoparticles
are a class of powerful immune carrier. In this talk, we will present our results in
using Qbeta for the development of new glycoconjugate based anti-Salmonella
Salmonella infections (salmonellosis) are a major public health problem throughout the world. Conventionally, invasive Salmonella infections are treated with antimicrobial agents. However, the overuse of antibiotics in medicine as well as in livestock rearing has led to the emergence of multidrug resistant strains, prompting the Centers for Disease Control and Prevention to designate Salmonella as a pathogen of serious concern in their report on antimicrobial threats in the USA. Despite the frequency and severity of non-typhoidal Salmonella (NTS) diseases, no licensed human NTS vaccines are available yet. There is an urgent need to develop an NTS vaccine that could complement other control and prevention strategies.
There are multiple strains of NTS Salmonella, including Salmonella enteritidis, Salmonella paratyphi A, and Salmonella typhimurium. The O-polysaccharides on these bacteria share a common polysaccharide backbone consisting of a trisaccharide repeat unit, which is further modified with a characteristic deoxy sugar unit. Our first generation vaccine focuses on targeting the tetrasaccharide characteristic of each strain. Chemical syntheses have been performed to produce the antigenic determinant tetrasaccharide associated with Salmonella enteritidis and Salmonella paratyphi A. The tetrasaccharides were then covalently conjugated with a powerful carrier, bacteriophage Qbeta. High levels of specific and long-lasting anti-glycan IgG antibodies were induced by the conjugate, which completely protected mice from lethal bacterial challenge in a passive transfer model. Glycan profiling of the antibodies produced indicated exquisite structural selectivities against the immunizing antigens. These results have provided exciting leads for the creation of new anti-Salmonella vaccines.
- BA and MA at Seoul National University, majoring Economics
- Ph.D. at Princeton University in Economics
- Spent two years at KISDI, Korean government think-tank for telecommunication and IT policy
- Professor of Economics at HUFS from year 1997
- Former president of Korea Academic Society for Industrial Organization
- Current president of Korea Society for Bioeconomy
- Has published academic papers in the fields of Industrial economics, innovation, regulations
· Trend of diffusion of coronavirus and policy responses
- Short history of the pandemic in Korea
- Disease control policies: testing, contact tracing
· Economic impact and policy initiatives
- Trends in macroeconomic indices: GDP, employment, trade
- Stimulation packages
· Changes and issues in post-corona era
- Untact digital society
- Global value chain
- Korean new-deal policy initiative: digital and green deal
- R&D in bio-medical innovation
Youn Hee Choi received her bachelor’s, master’s and doctoral degree from Seoul National University’s College of Engineering, majoring in biochemical engineering. She worked at the Institute for Molecular and Cellular biology at Osaka University in Japan, and as a post-doc. researcher at Stanford University’s Department of Chemical Engineering. She has worked at the Korea Institute for Industrial Economics and Trade since 2001, and focuses on researching new industry development and innovation policy, and in particular on bioindustry policy. She participated in development of various innovation policies with the Korean government, including with the Ministry of Economy and Finance, the Ministry of Trade, Industry and Energy, the Ministry of Science and ICT, and the Ministry of Health and Welfare. She also serves as a consultant for various public organizations and local governing bodies.
The bioeconomy in the era of Covid-19 will be discussed in the seminar and it could
be a good chance for everyone to understand the bioeconomy in terms of holistic
point of view.
The presentation is divided into four chapters. In the first chapter of prologue, the keywords and essential definitions of the bioeconomy would be summarized. Also, what bio-economy means in the era of the 4th industrial revolution would be emphasized.
In the Chapter 2, we can understand the global demand factors and environmental changes surrounding the bioeconomy, and also look at how the bioeconomy will be developed by 2030.
Chapter 3 briefly introduce the current status of the Korean bioeconomy supported by the various national policy efforts and, also the presentation show you some evaluations on the Korean competitiveness from the global perspectives.
In the last chapter, we reflect on what issues have been problems to revitalize the bioeconomy in terms of policy, and point out the major issues that need to be improved in the future.
The presentation does not suggest any quick solution to the major problems in the Korean bioeconomy in the era of Covid-19. However, we could begin the first step of contemplating some solutions together with the discussion in the seminar.
Dr. Park is a Chief Investment Officer at STIC ventures and leads bio-healthcare
group at STIC. He joined STIC Ventures spun off from STIC Investments in July,
Prior to joining to STIC Ventures, Dr. Park had worked as a Managing Partner at STIC Investments from February, 2006. He also worked for Samsung Venture Investment Corporation and Green Cross Bio Investment.
Dr. Park worked in London School of Hygiene and Tropical Medicine(LSHTM) as a Visiting Research Fellow. He holds master’s degree and Ph.D degree in Biochemical Engineering and Biotechnology from Seoul National University. And he studied Applied Biology and Chemistry in Seoul National University.
His main investment portfolios includes Medytox, Viewworks, i-Sens, Genic, Crystal Genomics, Access Bio(US), Triplex International Biosciences(China), Nanogen Biopharmaceutical(Vietnam). He also serves for Korean Government and Korea Exchange and major hospitals as an advisory member. And Dr. Park won commendations from Minister in Ministry of Trade, Industry and Technology and Ministry of SMEs and Startups in 2011 and 2018.
It is no exaggeration to say that the world has virtually stopped for more than six months due to a single virus, and this is expected to continue for a while. Controversy continues that this will have a lot of influence on people's behavior, consumption behavior, and meeting type. I would like to see how the investment trend before and after COVID 19 changed and how it will change in the future. In particular, we will consider what will be the result of investment in the bio-healthcare field.